Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma

Status Completed

Clinical Trial Summary

RATIONALE: Injecting allovectin-7 into a person's melanoma cells may make the body build an immune response that will kill tumor cells.

PURPOSE: Phase II trial to study the effectiveness of gene therapy in treating patients who have stage III or stage IV melanoma that has not responded to previous treatment.

Clinical Trial Description

OBJECTIVES: I. Demonstrate an objective clinical response (partial or complete) with a median duration of at least 4 months in 15% of patients with stage III or IV melanoma treated with Allovectin-7. Allovectin-7 is a direct gene transfer immunotherapeutic agent.

II. Determine the benefits, risks, and side effects of Allovectin-7 in this patient population.

PROTOCOL OUTLINE: This is a multicenter study. Patients receive an intratumoral injection of Allovectin-7 once weekly for 6 weeks. At week 9, a complete disease status assessment is performed. Patients with stable or responding disease may receive additional courses of 6 injections.

PROJECTED ACCRUAL:

A total of 70 patients will be accrued for this study. ;

Study Design

Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00003646
Study type	Interventional
Source	Vical
Contact
Status	Completed
Phase	Phase 2
Start date	August 1998
Completion date	May 2002

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02107755` - Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma	Phase 2
Withdrawn	`NCT01216787` - RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery	Phase 2
Active, not recruiting	`NCT01026324` - Dinaciclib in Treating Patients With Stage III-IV Melanoma	Phase 1/Phase 2
Completed	`NCT01010984` - LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma	N/A
Completed	`NCT00553306` - Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma	Phase 1/Phase 2
Completed	`NCT00121225` - Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma	Phase 2
Completed	`NCT00019448` - Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma	Phase 2
Active, not recruiting	`NCT03200847` - Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma	Phase 1/Phase 2
Active, not recruiting	`NCT03235245` - Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib	Phase 2
Terminated	`NCT01875653` - Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma	Phase 3
Completed	`NCT01748747` - Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery	Early Phase 1
Terminated	`NCT01316692` - Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma	Phase 2
Active, not recruiting	`NCT01120275` - Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma	Phase 2
Terminated	`NCT01217411` - RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer	Phase 1
Terminated	`NCT01026051` - Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma	Phase 2
Terminated	`NCT01166126` - Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV	Phase 2
Completed	`NCT01037790` - Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer	Phase 2
Completed	`NCT00288041` - Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma	Phase 2
Completed	`NCT00072163` - Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma	Phase 2
Completed	`NCT00074308` - Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers	Phase 1/Phase 2